Urology News and Research

Latest Urology News and Research

Top cancer hospitals have Elekta solutions for information management

Y chromosome may be responsible for a range of sex disorders

The unique mechanism behind the evolutionary survival of the human Y chromosome may also be responsible for a range of sex disorders, from failed sperm production to sex reversal to Turner Syndrome.

3 Sep 2009

Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors

Endo Pharmaceuticals (Nasdaq: ENDP) today announced the availability of VALSTAR(TM) (valrubicin) for the treatment of a distinct form of bladder cancer. VALSTAR is the only FDA-approved intravesical therapy for patients with Bacille Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder for whom immediate removal of the bladder would be associated with unacceptable medical risks.

3 Sep 2009

Uroplasty highlights the result of OrBIT trial of its Urgent PC System

Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results published in the September, 2009 edition of THE JOURNAL OF UROLOGY(R) from the OrBIT trial of its Urgent PC System.

3 Sep 2009

New findings on molecular imaging and prostate cancer

A new study published in the September issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET)/computer tomography (CT) scans with the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed.

2 Sep 2009

FDA approves Watson Pharmaceuticals' ANDA for Levonorgestrel tablets

Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Levonorgestrel Tablets, 0.75 mg for over-the-counter use in women ages 17 and above, as well as for prescription use in women under the age of 17.

29 Aug 2009

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.

26 Aug 2009

P&G's global pharmaceuticals business sold to Warner Chilcott for $3.1 billion

The Procter & Gamble Company and Warner Chilcott plc today announced an agreement for the sale of P&G's global pharmaceuticals business to Warner Chilcott for an up-front cash payment of $3.1 billion.

24 Aug 2009

FDA issues complete response letter regarding the NDA for carisbamate

The U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for carisbamate, an anti-epileptic drug in development, announced Ortho-McNeil-Janssen Pharmaceuticals, Inc.

23 Aug 2009

Results of PCF funded study could impact the standard of care for prostate cancer patients

Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).

21 Aug 2009

New findings to prevent urinary tract infections

Researchers at Duke University Medical Center may have a new way to stop and even prevent the urinary tract infections (UTIs) that plague more than a third of all adults, some of them repeatedly.

21 Aug 2009

Physician shortage limits even insured patients' access to care

CBS News reports that just having insurance coverage "doesn't guarantee access" to health care, because there is s shortage of primary care doctors to provide treatment. "Baystate Medical Center is the second busiest emergency room in Massachusetts. They treat over 100,000 patients a year, but here's the thing: according to Dr. Niels Rathlev, who runs the ER, a quarter of them don't need his services." Rathlev says it would be "more appropriate" for those people to see a primary care doctor. "'The majority of patients who are frequent utilizers of the emergency department actually have insurance,' Rathlev said. 'They have a primary care physician, but they choose to come to the ER because they don't have access.'"

20 Aug 2009

Health Informatics Consulting to oversee practice management & EHR implementation at New Jersey ambulatory centers

Two new ambulatory surgical centers under construction in Northern New Jersey will streamline and improve the quality of care for patients through a partnership with Health Informatics Consulting (http://www.hi-consulting.net), a leader in healthcare technology.

20 Aug 2009

Watson Pharmaceuticals offers unsecured notes up to $850 million

Watson Pharmaceuticals, Inc. (NYSE: WPI), a specialty pharmaceutical company, today announced that it is offering up to $850 million aggregate principal amount of five and ten year senior unsecured notes in a registered public offering.

19 Aug 2009

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

AEterna Zentaris Inc. today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

17 Aug 2009

Obesity leads to worse prostate cancer in both black and whites equally

A new look at a large database of prostate cancer patients shows that obesity plays no favorites when it comes to increasing the risk of recurrence after surgery: Being way overweight is equally bad for blacks and whites, say researchers at Duke University Medical Center.

13 Aug 2009

$Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer$

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.

11 Aug 2009

Importance of PSA testing in high-risk men, stressed by National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Prostate Cancer Early Detection incorporating the results of the recent ERSPC trial that assessed the benefit of PSA screening. The NCCN Guidelines contend that PSA screening does save lives when performed intelligently in men at high-risk of developing the disease.

11 Aug 2009

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that Astellas will undertake a single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. The trial, to be called ACT 5, is expected to begin enrolling patients by the end of 2009, with completion expected in the first half of 2011.

11 Aug 2009

Watson recalls one lot of Fentanyl transdermal system

Watson Pharmaceuticals has announced that one lot of 100 mcg/hr Fentanyl Transdermal System patches sold in the United States is being voluntarily recalled from wholesalers and pharmacies.

9 Aug 2009

Urology News and Research

Latest Urology News and Research

Top cancer hospitals have Elekta solutions for information management

Y chromosome may be responsible for a range of sex disorders

Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors

Uroplasty highlights the result of OrBIT trial of its Urgent PC System

New findings on molecular imaging and prostate cancer

FDA approves Watson Pharmaceuticals' ANDA for Levonorgestrel tablets

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

P&G's global pharmaceuticals business sold to Warner Chilcott for $3.1 billion

FDA issues complete response letter regarding the NDA for carisbamate

Results of PCF funded study could impact the standard of care for prostate cancer patients

New findings to prevent urinary tract infections

Physician shortage limits even insured patients' access to care

Health Informatics Consulting to oversee practice management & EHR implementation at New Jersey ambulatory centers

Watson Pharmaceuticals offers unsecured notes up to $850 million

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

Obesity leads to worse prostate cancer in both black and whites equally

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Importance of PSA testing in high-risk men, stressed by National Comprehensive Cancer Network

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Watson recalls one lot of Fentanyl transdermal system

Industry Focus: Cell & Gene Therapy eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Urology News and Research

Latest Urology News and Research

Industry Focus: Cell & Gene Therapy eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in